Objective: The A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) trial has received fierce criticism, including considerable selection bias, poor generalizability, questionable clinical practices (only 15.8% underwent surgical resection, the gold standard for arteriovenous malformation [AVM] treatment), and short follow-up (33 months) for a disease process that carries a life-long risk. In this study, we sought to present our own experience treating unruptured brain AVMs to provide supporting evidence of the ARUBA trial criticism.
Methods: All cases of treated brain AVMs from 2004 to 2017 at our institution were retrospectively reviewed and included in the analysis if they met ARUBA trial inclusion criteria. The primary outcome was symptomatic stroke or death. Secondary outcomes included AVM obliteration, long-term clinical impairment (modified Rankin Scale score >1), and new major or minor postoperative deficit.
Results: Of the 245 reviewed cases, 86 met the ARUBA trial criteria. Treatment included microsurgical resection alone (2.3%), preoperative embolization followed by microsurgical resection (62.8%), stereotactic radiosurgery alone (10.5%), embolization followed by stereotactic radiosurgery (15.1%), and embolization alone (9.3%). The primary outcome was met in 8.3%, new perioperative major and minor complications occurred in 5.8% and 12.8%, and long-term clinical impairment in 4.5%. AVM obliteration was observed in 92.4% overall and in 100% of patients who underwent surgical resection.
Conclusions: The criticism of the ARUBA trial is warranted, as our study found that treatment of unruptured brain AVMs has an acceptable safety profile when approached in a multidisciplinary manner at an experienced institution, using surgical resection as the primary treatment modality when applicable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.wneu.2018.09.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Measurement Equivalence and Feasibility of the Electronic and Paper Versions of the POSAS, EQ-5D, and DLQI: A Randomized Crossover Trial.
Eur Burn J
October 2024
Oscare, Organization for Burns, Scar After-Care and Research, 2170 Antwerp, Belgium.
Patient-reported outcome measures (PROMs) are crucial within person-centered care. The use of electronic PROMs (ePROMs) is increasing and multiple advantages have been described. The Patient and Observer Scar Assessment Scale (POSAS) is a validated paper questionnaire to assess patient-reported scar quality in the burn and scar population.
View Article and Find Full Text PDFThe application of machine learning for treatment selection of unruptured brain arteriovenous malformations: A secondary analysis of the ARUBA trial data.
Clin Neurol Neurosurg
December 2024
Department of Neuroimaging Sciences, University of Edinburgh, Edinburgh, UK; Lothian Birth Cohort studies, Department of Psychology, University of Edinburgh, Edinburgh, UK; Department of Computer Science, Lagos State University, Nigeria. Electronic address:
Objective: To build a supervised machine learning (ML) model that selects the best first-line treatment strategy for unruptured bAVMs.
Methods: A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) trial data was obtained from the National Institute of Neurological Disorders and Stroke (NINDS). A team of five clinicians examined the demographic, clinical, and radiological details of each patient at baseline and reached a consensus on the best first-line treatment for bAVMs.
Uses of Fibrinogen Concentrate in Management of Trauma-Induced Coagulopathy in the Prehospital Environment: A Scoping Review.
Prehosp Emerg Care
November 2024
Division of Emergency Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Objectives: Trauma-induced coagulopathy remains a significant contributor to mortality in severely injured patients. Fibrinogen is essential for early hemostasis and is recognized as the first coagulation factor to fall below critical levels, compromising the coagulation cascade. Recent studies suggest that early administration of fibrinogen concentrate is feasible and effective to prevent coagulopathy.
View Article and Find Full Text PDFObjective: Sarpogrelate is a selective serotonin/5-hydroxytryptamine 2A receptor antagonist used in the management of peripheral artery disease (PAD). The drug has emerged as a promising choice for medical management post-endovascular therapy (EVT) due to its anti-platelet aggregation, vasoconstriction, and anti-vascular smooth muscle proliferation properties. The aim of the meta-analysis is to evaluate the efficacy and safety of sarpogrelate-based APT following arterial EVTs in PAD.
View Article and Find Full Text PDFSystematic reviews and meta-analyses in the cerebrovascular space: essential domains for readers.
Neurosurg Rev
August 2024
Department of Neurosurgery, University of Oklahoma, 1000 N Lincoln Blvd, #4000, Oklahoma City, OKC, 73104, USA.
Introduction: Systematic Review and Meta-Analysis (SRMAs) in neurosurgery have significantly increased. With approximately 1 million patients affected by cerebrovascular disease annually, interpreting SRMAs necessitates a systematic approach. The objective of this review is to identify and describe four essential domains for SRMA interpretation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!